{"id":11403831,"date":"2026-07-17T14:40:58","date_gmt":"2026-07-17T11:40:58","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&#038;p=11403831"},"modified":"2026-08-27T15:07:32","modified_gmt":"2026-08-27T12:07:32","slug":"xigduo-5mg-1000mg","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/xigduo-5mg-1000mg\/","title":{"rendered":"Xigduo 5 mg\/1000 mg Dapagliflozin + Metformin"},"content":{"rendered":"<p><strong>Xigduo<\/strong> 5 mg\/1000 mg combines dapagliflozin 5 mg with metformin hydrochloride 1000 mg in one prescription tablet for adults with type 2 diabetes. It is used alongside diet and physical activity when metformin alone, or metformin with other diabetes medicines, does not provide adequate control. This page explains its dual mechanism, appropriate use, monitoring and seven essential safety checks.<\/p>\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/nostylelike.net\/wp-content\/uploads\/2026\/07\/01-xigduo-5mg-1000mg-front.jpg\" alt=\"Xigduo 5 mg\/1000 mg dapagliflozin metformin front view\" width=\"1200\" height=\"1200\" loading=\"lazy\"><figcaption>Xigduo 5 mg\/1000 mg dapagliflozin and metformin film-coated tablets.<\/figcaption><\/figure>\n<h2>What is Xigduo 5 mg\/1000 mg?<\/h2>\n<p>Xigduo contains two glucose-lowering medicines with complementary actions. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It reduces glucose reabsorption in the kidneys, allowing more glucose to leave the body in urine. Metformin is a biguanide that mainly reduces glucose production by the liver and improves the body\u2019s response to insulin. Together, the two components help lower blood glucose in adults with type 2 diabetes.<\/p>\n<p>The Turkish pack may be labelled <strong>Xigduo XR<\/strong>. Release characteristics and instructions can differ between markets, so the exact Turkish leaflet supplied with the pack and the prescriber\u2019s directions take priority. Do not substitute an immediate-release and prolonged-release product or alter the tablet without advice from a pharmacist or doctor.<\/p>\n<h2>Approved use of Xigduo<\/h2>\n<p>The European authorisation covers adults with type 2 diabetes as an adjunct to diet and exercise in three situations:<\/p>\n<ul>\n<li>when the maximum tolerated dose of metformin alone does not control blood glucose adequately;<\/li>\n<li>when metformin together with other glucose-lowering medicines does not provide adequate control; or<\/li>\n<li>when replacing dapagliflozin and metformin that are already being taken as separate tablets.<\/li>\n<\/ul>\n<p>Xigduo is not a treatment for type 1 diabetes and it is not used to treat diabetic ketoacidosis. The decision to prescribe this fixed-strength combination depends on kidney function, the current metformin dose, other medicines and the individual treatment target. See the current <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xigduo\" target=\"_blank\" rel=\"noopener nofollow\">European Medicines Agency overview for Xigduo<\/a>.<\/p>\n<h2>How the two ingredients work<\/h2>\n<p>Dapagliflozin blocks SGLT2 in the kidneys. As a result, some filtered glucose is not returned to the bloodstream and is excreted in urine. This mechanism can increase urination and may contribute to fluid loss, so hydration and illness management are important. Metformin lowers hepatic glucose output and improves insulin sensitivity without usually causing hypoglycaemia on its own.<\/p>\n<p>When Xigduo is used with insulin or a sulfonylurea, however, low blood glucose can occur more often. The prescriber may need to review the dose of those medicines. Never reduce insulin or another diabetes medicine independently.<\/p>\n<h2>7 essential Xigduo safety checks<\/h2>\n<ol>\n<li><strong>Kidney function:<\/strong> kidney tests are required before treatment and periodically afterwards. Severe renal impairment is a contraindication because metformin can accumulate and dapagliflozin may not be appropriate.<\/li>\n<li><strong>Hydration and acute illness:<\/strong> vomiting, diarrhoea, fever, poor fluid intake, severe infection or dehydration can increase the risk of kidney problems, ketoacidosis and lactic acidosis. Contact the treating team promptly for sick-day advice.<\/li>\n<li><strong>Ketoacidosis symptoms:<\/strong> seek urgent medical care for nausea, vomiting, abdominal pain, excessive thirst, rapid or deep breathing, confusion, unusual sleepiness, or a sweet or metallic breath odour. Ketoacidosis can occasionally occur even when glucose is not extremely high.<\/li>\n<li><strong>Lactic acidosis risk:<\/strong> metformin-associated lactic acidosis is rare but life-threatening. Risk rises with severe kidney dysfunction, tissue hypoxia, major illness, liver impairment, dehydration or excessive alcohol use.<\/li>\n<li><strong>Infection symptoms:<\/strong> report burning urination, fever, back pain or genital itching, soreness, discharge or swelling. SGLT2 inhibitors increase glucose in urine and can increase genital infections and some urinary infections.<\/li>\n<li><strong>Surgery and contrast procedures:<\/strong> tell the surgeon and radiology team that you take metformin. Temporary interruption may be required around major surgery or iodinated contrast, with restart only after the clinician confirms that kidney function is stable.<\/li>\n<li><strong>Other medicines and conditions:<\/strong> provide a complete list of medicines, supplements and recent treatments. Diuretics, insulin, sulfonylureas, medicines affecting kidney function and heavy alcohol intake may require additional assessment.<\/li>\n<\/ol>\n<h2>Who should not take Xigduo?<\/h2>\n<p>According to the current product information, Xigduo must not be used in people with hypersensitivity to dapagliflozin, metformin or an excipient; acute metabolic acidosis including diabetic ketoacidosis or lactic acidosis; diabetic pre-coma; severe renal failure; significant liver impairment; acute conditions that may alter kidney function such as severe dehydration, infection or shock; diseases causing tissue hypoxia such as decompensated heart or respiratory failure, a recent heart attack or shock; acute alcohol intoxication or habitual excessive alcohol use.<\/p>\n<p>Pregnancy, breastfeeding, planned surgery, fasting, a very-low-carbohydrate diet or a history of ketoacidosis should be discussed with the prescriber before treatment. Children and adolescents should not use this strength unless specifically authorised in the relevant national product information.<\/p>\n<h2>Possible side effects<\/h2>\n<p>Common effects can include nausea, vomiting, diarrhoea, abdominal discomfort, reduced appetite, altered taste, increased urination, urinary tract infection and genital fungal infection. Gastrointestinal effects are often linked to metformin, particularly at the start of treatment. Dapagliflozin can contribute to thirst, dizziness or signs of dehydration.<\/p>\n<p>Hypoglycaemia is more likely when Xigduo is combined with insulin or a sulfonylurea. Symptoms may include sweating, shaking, hunger, palpitations, confusion or weakness. Follow the diabetes team\u2019s individual plan for recognising and treating low glucose.<\/p>\n<p>Rare but serious reactions include diabetic ketoacidosis, lactic acidosis, severe dehydration, serious urinary infection, allergic reaction and necrotising fasciitis of the perineum (Fournier\u2019s gangrene). Severe pain, redness or swelling around the genital or perineal area with fever or feeling unwell requires emergency assessment.<\/p>\n<h2>Monitoring during treatment<\/h2>\n<ul>\n<li>HbA1c and home glucose readings according to the diabetes plan.<\/li>\n<li>Kidney function before treatment and at intervals determined by the clinician.<\/li>\n<li>Blood pressure, hydration and weight where clinically appropriate.<\/li>\n<li>Vitamin B12 assessment if anaemia, neuropathy or long-term metformin use raises concern.<\/li>\n<li>Review of infections, foot health and cardiovascular risk as part of routine diabetes care.<\/li>\n<\/ul>\n<p>Keeping appointments remains important even when glucose readings improve. The fixed combination supports diabetes control but does not replace healthy eating, activity, eye screening, kidney monitoring or management of blood pressure and cholesterol.<\/p>\n<h2>How to take the Turkish Xigduo pack safely<\/h2>\n<p>Take only the dose and schedule printed on the dispensing label and prescribed for you. Swallow the tablet as directed in the Turkish leaflet, and do not crush, split or change an XR tablet unless the leaflet and pharmacist explicitly permit it. If a dose is missed, follow the official leaflet rather than doubling the next dose. Never share prescription diabetes medicine.<\/p>\n<h2>Storage and handling<\/h2>\n<p>Follow the storage statement on the Turkish pack. Keep the medicine in its original packaging, out of the sight and reach of children, and do not use it after the expiry date or if the blister is damaged. The current European leaflet states that the medicine does not require special storage conditions. For detailed handling and safety information, review the current <a href=\"https:\/\/www.medicines.org.uk\/emc\/product\/7612\/smpc\" target=\"_blank\" rel=\"noopener nofollow\">Xigduo 5 mg\/1000 mg Summary of Product Characteristics<\/a>.<\/p>\n<h2>Ordering Xigduo from No Style Like<\/h2>\n<p>No Style Like provides information about specialist and imported medicines. Visit the <a href=\"https:\/\/nostylelike.net\/en\/\">English homepage<\/a> or contact support before ordering to confirm current availability, Turkish pack details, prescription requirements and shipping arrangements. Product availability is not a medical recommendation.<\/p>\n<h2>Medical notice<\/h2>\n<p>This information does not replace the official Turkish leaflet, the dispensing label or advice from a qualified healthcare professional. Xigduo requires an individual treatment plan and ongoing monitoring. Do not start, stop or change dapagliflozin, metformin, insulin or any other diabetes treatment without the prescriber.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xigduo 5 mg\/1000 mg combines dapagliflozin and metformin for adults with type 2 diabetes. Learn its approved use, monitoring, key warnings and safe handling.<\/p>\n","protected":false},"featured_media":11404694,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[42027],"product_tag":[],"class_list":["post-11403831","product","type-product","status-publish","has-post-thumbnail","product_cat-diabetes-blood-pressure","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/comments?post=11403831"}],"version-history":[{"count":2,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403831\/revisions"}],"predecessor-version":[{"id":11404703,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403831\/revisions\/11404703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media\/11404694"}],"wp:attachment":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media?parent=11403831"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_brand?post=11403831"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_cat?post=11403831"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_tag?post=11403831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}